August 7, 2020

Zomedica Adds Two New Directors To Board Annual Meeting Materials Availability

August 3, 2020

Zomedica Announces Management Change

July 21, 2020

Successful Remote Installation of TRUFORMA™

July 7, 2020

Zomedica Pharmaceuticals Corp. Closes $30 Million Public Offering

July 1, 2020

Zomedica Pharmaceuticals Corp. Announces $30 Million Public Offering

July 1, 2020

Zomedica Pharmaceuticals Corp. Announces Proposed Public Offering

June 16, 2020

Zomedica Appoints New Interim CEO to Lead Organization Through Inaugural Product Launch

May 29, 2020

Zomedica Pharmaceuticals Corp. Closes $20 Million Public Offering

May 26, 2020

Zomedica Pharmaceuticals Corp. Announces $20 Million Public Offering

May 20, 2020

Zomedica Completes Verification of Three More Assays for its TRUFORMA™ Point-of-Care Diagnostic Platform

May 11, 2020

Zomedica Announces First Quarter 2020 Financial Results

April 21, 2020

Zomedica Completes Verification of its TRUFORMA™ Point-of-Care Diagnostic Platform and the First Assay, Canine total T4

April 13, 2020

Zomedica Provides Corporate Update

April 7, 2020

Zomedica Pharmaceuticals Corp. Announces Pricing of $4.0 Million Public Offering

April 7, 2020

Zomedica Pharmaceuticals Corp. Announces Public Offering

February 26, 2020

Zomedica Pharmaceuticals Corp. Announces Year End 2019 Financial Results

February 14, 2020

Zomedica Announces Completion of $2.5 Million Registered Direct Offering

February 12, 2020

Zomedica Announces $2.5 Million Registered Direct Offering

February 11, 2020

Zomedica Files U.S. Patent Application for Fecal Parasite Detection

January 30, 2020

Zomedica to Voluntarily Delist its Common Shares from TSX Venture Exchange Effective February 10, 2020

January 23, 2020

Zomedica to Focus on TRUFORMA™ Commercialization

January 20, 2020

Zomedica Successfully Completes Development and Manufacturing Milestones for its Cancer Liquid Biopsy Platform